Overcoming mechanism of treatment resistance in castration-resistant prostate cancer: Defining a new treatment paradigm

Prostate cancer is the second leading cause of male cancer mortality in Ireland: in 2012, 533 men died from this disease.Prostate cancer growth is stimulated by male sex hormones (androgens) e.g. testosterone. The mainstay of initial treatment is to block gonadal production of these hormones. However, with time, cancers develop other mechanisms of resistance despite castrate levels of testosterone known as castration resistant prostate cancer (CRPC). Unfortunately, this advanced form of prostate cancer is currently incurable.

Award Date
16 May 2014
Award Value
€221,142
Principal Investigator
Dr Anuradha Jayaram
Host Institution
St. James's Hospital
Scheme
Research Training Fellowships for Healthcare Professionals